The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition

被引：0

作者：

Chander Peddaboina

Daniel Jupiter

Steven Fletcher

Jeremy L Yap

Arun Rai

Richard P Tobin

Weihua Jiang

Philip Rascoe

M Karen Newell Rogers

W Roy Smythe

Xiaobo Cao

机构：

[1] The Texas A&M University System,Department of Surgery, Scott & White Memorial Hospital and Clinic

[2] Health Science Center,Department of Pharmaceutical Sciences

[3] College of Medicine,undefined

[4] University of Maryland School of Pharmacy,undefined

[5] Boston University School of Medicine,undefined

来源：

BMC Cancer | / 12卷

关键词：

Mcl-1; Bcl-xL; USP9X; Ubiquitination; Cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Mcl-1, Bcl-xL and cell cycle inhibition by GCS-100:: A novel therapy for myeloma.
Streetly, Matthew
Su, Bo
Carver, Bradley
Schey, Stephen A.
Cotter, Finbarr E.
BLOOD, 2006, 108 (11) : 990A - 990A
[22] Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells
Lincet, Hubert
Kafara, Perrine
Giffard, Florence
Abeilard-Lemoisson, Edwige
Duval, Maryline
Louis, Marie-Helene
Poulain, Laurent
Icard, Philippe
JOURNAL OF OVARIAN RESEARCH, 2013, 6
[23] Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells
Hubert Lincet
Perrine Kafara
Florence Giffard
Edwige Abeilard-Lemoisson
Maryline Duval
Marie-Hélène Louis
Laurent Poulain
Philippe Icard
Journal of Ovarian Research, 6
[24] Dual Inhibition of BCL-XL and MCL-1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition
Weeden, C.
Ah-Cann, C.
Holik, A.
Merino, D.
Lessene, G.
Asselin-Labat, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S457 - S457
[25] Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
Clare E. Weeden
Casey Ah-Cann
Aliaksei Z. Holik
Julie Pasquet
Jean-Marc Garnier
Delphine Merino
Guillaume Lessene
Marie-Liesse Asselin-Labat
Oncogene, 2018, 37 : 4475 - 4488
[26] Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
Weeden, Clare E.
Ah-Cann, Casey
Holik, Aliaksei Z.
Pasquet, Julie
Garnier, Jean-Marc
Merino, Delphine
Lessene, Guillaume
Asselin-Labat, Marie-Liesse
ONCOGENE, 2018, 37 (32) : 4475 - 4488
[27] Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition
Roldan-Romero, Juan M.
Valdivia, Carlos
Santos, Maria
Lanillos, Javier
Maroto, Pablo
Anguera, Georgia
Calsina, Bruna
Martinez-Montes, Angel
Monteagudo, Maria
Mellid, Sara
Leandro-Garcia, Luis J.
Montero-Conde, Cristina
Cascon, Alberto
Roncador, Giovanna
Coloma, Javier
Robledo, Mercedes
Rodriguez-Antona, Cristina
INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1300 - 1312
[28] Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction
Gomez-Bougie, Patricia
Menoret, Emmanuelle
Juin, Philippe
Dousset, Christelle
Pellat-Deceunynck, Catherine
Amiot, Martine
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 413 (03) : 460 - 464
[29] Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
Schneller, Anja
Zojer, Niklas
Bolomsky, Arnold
Ludwig, Heinz
HAEMATOLOGICA, 2021, 106 (09) : 2516 - 2521
[30] MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
Vikstrom, Ingela B.
Slomp, Anne
Carrington, Emma M.
Moesbergen, Laura M.
Chang, Catherine
Kelly, Gemma L.
Glaser, Stefan P.
Jansen, J. H. Marco
Leusen, Jeanette H. W.
Strasser, Andreas
Huang, David C. S.
Lew, Andrew M.
Peperzak, Victor
Tarlinton, David M.
CELL DEATH & DISEASE, 2016, 7 : e2345 - e2345

← 1 2 3 4 5 →